Medicon Valley Biomedical Newsletter

Active Biotech AB and Chelsea Therapeutics International have signed an agreement to co-develop and commercialize the I-3D portfolio of orally active compounds inhibiting dihydroorotate dehydrogenase,...

BioGaia has signed a distribution agreement with Laboratoire Physcience in France giving Physcience exclusive rights to sell BioGaia´s Reuteri tablets in France and Belgium. Laboratoire Physcie...

A blood sample from patients with advanced colon cancer can reveal whether the traditional chemotherapy has the intended effect or not. A novel Danish-Swedish collaboration has researched into the ser...

The Swedish Medical Products Agency has approved Camurus' Clinical Trial Application for Phase I trials of CAM2029, the company's product candidate for the treatment of acromegaly and carcinoi...

Following the presentation of the results of the Phase IIb programme with Degarelix in prostate cancer, which are in line with previous promising studies, Ferring Pharmaceuticals has announced the sta...

Gambro AB has announced that it intends to acquire the assets and operations of Hemapure AB, a Swedish venture funded company. All employees will transfer to Gambro. Hemapure has developed a new innov...

H. Lundbeck A/S has filed an application for approval of Cipralex, escitalopram, for the treatment of obsessive-compulsive disorder, OCD, in the EU with the health authorities in Sweden, which acts as...

The medical faculty of Lund University has decided to strengthen the research into neuroscience by starting up of a novel scientific platform focusing on the brain and its related diseases. The goal...

Novo Nordisk A/S and the French biopharmaceutical company Innate Pharma SA have announced a major partnership to develop new drugs targeting natural killer, NK, cells. As part of the agreement, Novo N...

Nycomed has announced that the Swedish health authorities have approved ZyComb, the first combination nasal spray for the simultaneous treatment of the two major symptoms of the common cold - nasal co...

The European Commission has approved and issued EU marketing authorisation for Nycomed's new osteoporosis product, Preotact. Nycomed and its US collaborator NPS Pharmaceuticals Inc. have an...

Pharmexa A/S has received the first approvals from the authorities regarding the PrimoVax Phase III trial with GV1001 and will now initiate recruitment of patients. The trial has so far been approved ...

The contract research organisation PhaseOneTrials A/S has entered an agreement with US-based Schering Plough Research Institute. PhaseOneTrials and Schering Plough will in collaboration perform an adv...

TopoTarget A/S announced that their application for marketing approval of Totect has been accepted by the FDA for review. Totect has also been granted priority review status by the FDA. Totect will be...

After years of extensive research and development, ViroGates A/S has completed production of the first batch of suPARnostic kits for the monitoring of HIV disease progression. The suPARnostic kit will...

Sanofi-Aventis has initiated a double blind, placebo controlled Phase II dose ranging study for the GLP-1 Agonist AVE0010 (ZP10) in Metformin-treated patients with Type 2 diabetes. AVE0010, ZP10, was ...